戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              Intrapleural administration of MPM cells expressing tiss
2                           In conclusion, the intrapleural administration of TGF-beta2 produced excell
3                          We hypothesize that intrapleural administration of TGF-beta2 would (1) produ
4 MPM cells promotes tumor cell apoptosis, and intrapleural EPCR gene therapy suppresses MPM progressio
5                                              Intrapleural fibrin precedes visceral-parietal pleural a
6                                              Intrapleural fibrinolysis with urokinase or alteplase fa
7 ed fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcom
8                                              Intrapleural HO-1 induction inhibited PMC migration afte
9 vel than did the fluid that results from the intrapleural injection of 10 mg/kg doxycycline or 400 mg
10                                              Intrapleural injection of Ad.EPCR into mice with an esta
11 i-inflammatory agents, tube thoracostomy, or intrapleural injection of sclerosing agents.
12             One group of rabbits received an intrapleural injection of talc (400 mg/kg) and an intram
13  induce less inflammation when compared with intrapleural injection of talc.
14                                              Intrapleural injection of TGF-beta(2) induced a dose-dep
15 asis of this study we conclude that a single intrapleural injection of TGF-beta(2) induces pleurodesi
16                                     A single intrapleural injection of TGF-beta(2) may produce a pleu
17                                          The intrapleural injection of TGF-beta(2) resulted in a dose
18                                              Intrapleural injection of TGF-beta2 produced effective p
19                                              Intrapleural injection of the larger doses of TGF-beta(2
20 e present study was to determine whether the intrapleural injection of transforming growth factor bet
21                                       Single intrapleural injections of TGF-beta(2) at doses of 5.00
22 treated with thoracostomy tube placement and intrapleural instillation of either urokinase or altepla
23                          The optimal role of intrapleural L-NDDP therapy currently remains to be dete
24                                              Intrapleural L-NDDP therapy in this patient population i
25                                              Intrapleural loculation can increase morbidity in hemoth
26                    On day 7 a single dose of intrapleural LTA-T (increasing in each patient) was admi
27                         The toxic effects of intrapleural LTA-T seem to be mild and favourable when c
28 tricular end-systolic pressure) of increased intrapleural pressure in dilated ventricles.
29 hallenge were also correlated with increased intrapleural pressure, measured via an esophageal tube.
30 t of positive-pressure-mediated increases in intrapleural pressure.
31 irway pressures of approximately 7 mm Hg and intrapleural pressures of approximately 3 mm Hg in both
32                            A control dose of intrapleural saline was administered after complete drai
33                             In rabbits given intrapleural single-chain urokinase 24 and 48 hours afte
34                                              Intrapleural siRNA delivery has considerable potential a
35 c motor neurons, and PKCtheta knockdown with intrapleural siRNAs abolishes pLTF.
36                                              Intrapleural siRNAs targeting PKCzeta, an atypical PKC i
37                                              Intrapleural t-PA-DNase therapy improved fluid drainage
38 single-chain urokinase 24 and 48 hours after intrapleural tetracycline (n = 10 animals), adhesions we
39                                              Intrapleural therapy using interferon gamma, particularl
40 study treatments for 3 days: double placebo, intrapleural tissue plasminogen activator (t-PA) and DNa
41 s data have shown that the combination of an intrapleural tissue plasminogen activator and deoxyribon
42 , 55 years; 44 male, 22 female) who received intrapleural tPA between 2000 and 2006 was performed.
43                                              Intrapleural tPA is effective in improving drainage of l
44 ulation does not increase bleeding risk with intrapleural tPA, but therapeutic anticoagulation is ass
45                  To compare chest drain with intrapleural urokinase and primary video-assisted thorac
46 is no difference in clinical outcome between intrapleural urokinase and VATS for the treatment of chi
47 receive either percutaneous chest drain with intrapleural urokinase or primary VATS.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。